With commercial insurance: OCREVUS Co-pay Program; same program for Ocrevus and Ocrevus Zunovo — as little as $0, up to $20,000 per calendar year. With Medicare: the Ocrevus card can’t be used. TotalAssist (Patient Advocate Foundation) – Multiple sclerosis (MS) is open as of September 28, 2026.
See what this patient owes after assistance →
7 assistance programs for Ocrevus patients · 3 open today
Two Genentech programs: the OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo, a $0 commercial copay card covering up to $20,000 a year for the drug plus administration separately, and Genentech Patient Foundation, free drug for uninsured patients, patients whose coverage falls short and some commercially insured patients who meet the program's rules. Three foundation funds add a Medicare route: PAN Foundation Multiple sclerosis (MS), paying up to $8,000 a year, HealthWell's Multiple Sclerosis Medicare Access fund, and Good Days' Multiple Sclerosis fund; check each fund's current status on the funds list.
Select the patient's insurance and diagnosis to see which programs apply.
Current status · Award amounts · Eligibility · Direct application links October 12, 2026
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Ocrevus’s card can’t be used with Medicare. These funds may help. They open and close with donations, so call before telling a Ocrevus patient no.
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Ocrevus · Relapsing MS · Commercial insurance
Eligible patients may pay $0
Example · Ocrevus · 600 mg · 600 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo | |
|---|---|---|
| Drug responsibility | $7,282.68 | $0.00 |
| Administration (96413 + 96415) | $38.01 | $0.00 |
| Patient owes | $7,320.69 | $0.00 |
Estimated patient savings: $7,320.69
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Maximum award $8,000
PAN Foundation fund for government-insured patients with Multiple sclerosis (MS) (confirmed diagnosis).
Maximum award Contact Good Days
Good Days fund for government-insured patients with Multiple Sclerosis (confirmed diagnosis).
Maximum award $8,000
HealthWell Foundation fund for government-insured patients with Multiple Sclerosis (confirmed diagnosis).
Also available if this patient’s coverage falls short
Free Genentech Patient Foundation for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
| Task | ✓ |
|---|---|
| Find programs for the diagnosis | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance: The OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo is Genentech's commercial copay card. Eligible patients pay $0 for the drug, up to $20,000 a calendar year, and the program pays administration separately, up to $1,500 in the first calendar year and $1,000 each year after. An Ocrevus claim carries the drug line (J2350, 600 units for the 600 mg maintenance dose from two 300 mg vials) and the administration lines (96413 for the first hour, 96415 twice for the remaining hours of the 3.5-hour infusion); the card can zero out both up to its caps. It excludes Medicaid, Medicare, and other government insurance. View current program ↑
Uninsured: Genentech Patient Foundation ships Ocrevus free to eligible uninsured patients, patients whose coverage falls short and some commercially insured patients who meet the program's rules who meet the program's income rules. Only the drug arrives free; the infusion charge is still billed to the patient separately.
Medicare: Manufacturer copay savings cannot be used when government insurance is paying for Ocrevus; the federal Anti-Kickback Statute is why, per HHS OIG guidance on copayment coupons. The OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo excludes Medicare outright, and Genentech Patient Foundation takes uninsured patients, patients whose plan does not cover Ocrevus, and insured patients whose plan's out-of-pocket maximum is more than 7.5% of household income, within its income limits. What's available instead is the PAN Foundation Multiple sclerosis (MS) fund, which accepts Medicare and pays up to $8,000 a year toward the drug; HealthWell's Medicare Access fund and Good Days' fund also accept Medicare (check each fund's current status on the funds list). On the 600 mg maintenance dose, a Medicare patient's 20% coinsurance is $7,320.69 on the $36,603.45 Medicare allows, once the Part B deductible is met, and no manufacturer program reduces it. See Medigap out-of-pocket by plan →
Why the diagnosis selector doesn't change the result: None of the programs above is gated by indication beyond the label itself. Relapsing forms of multiple sclerosis (G35.A), primary progressive MS (G35.B1) and active secondary progressive MS (G35.C1) all qualify the same programs; eligibility runs on insurance status, not on which indication is billed.
Yes. The OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo is Genentech's commercial copay card: eligible patients pay $0 for the drug, up to $20,000 a calendar year, plus administration separately (up to $1,500 in the first calendar year and $1,000 each year after). It excludes Medicaid, Medicare, and other government insurance. Apply on Ocrevus.com ↗ Calculate cost with the program →
Yes, separately from the drug. The card pays up to $1,500 toward administration in the first calendar year and $1,000 each year after, on top of its $20,000 drug cap. The maintenance infusion bills 96413 for the first hour and 96415 twice for the remaining hours of the 3.5-hour infusion. View current program ↑
Not through Genentech's copay programs. The OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo excludes Medicare and Medicaid outright, and Genentech Patient Foundation takes uninsured patients, patients whose plan does not cover Ocrevus, and insured patients whose plan's out-of-pocket maximum is more than 7.5% of household income, within its income limits. What's available instead is the PAN Foundation Multiple sclerosis (MS) fund, which accepts Medicare and pays up to $8,000 a year toward the drug; HealthWell's Medicare Access fund and Good Days' fund also accept Medicare (check each fund's current status on the funds list). See Medigap out-of-pocket by plan →
Yes. The PAN Foundation Multiple sclerosis (MS) fund pays up to $8,000 a year toward the drug for commercial or Medicare patients; check each fund's current status on the funds list. HealthWell Foundation's Multiple Sclerosis - Medicare Access fund and Good Days' Multiple Sclerosis fund also apply; check each fund's current status on the funds list. Check today's status ↑
Call 888-941-3331 or apply online. Genentech Patient Foundation ships Ocrevus free to eligible uninsured patients, patients whose coverage falls short and some commercially insured patients who meet the program's rules who meet the program's income rules; the infusion line still goes on the patient's bill. Apply through Genentech ↗
The OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo and the PAN Foundation funds reduce what a patient owes on an approved, paid claim; neither applies to a denied claim. The denial has to be resolved through the payer's appeal or reconsideration process before any of these programs has anything to apply to.
Ocrevus shares its class with Ocrevus Zunovo (J2351, Genentech), Briumvi (J2329, TG Therapeutics), Tysabri (J2323, Biogen), Lemtrada (J0202, Sanofi), billed under their own codes with their own manufacturer programs. The programs above apply to Ocrevus only. If the payer requires Ocrevus Zunovo, Briumvi, Tysabri or Lemtrada instead of Ocrevus, use that maker’s program below.
Each Ocrevus Zunovo, Briumvi, Tysabri or Lemtrada card shows the date we last checked that program. Copay cards also say whether they pay the infusion or injection fee.
OCREVUS Co-pay Program (same program covers OCREVUS ZUNOVO)
Genentech Patient Foundation (Ocrevus Zunovo)
BRIUMVI Co-pay Assistance Program
BRIUMVI Patient Assistance Program
Free Drug Program (Biogen Support Services)
Biogen Copay Program
LEMTRADA Co-Pay Program (MS One to One)
MS One to One Patient Assistance Program
Data current: programs verified Oct 12, 2026
Genentech (OCREVUS Co-pay Program (drug co-pay + separate administration co-pay); same program for Ocrevus and Ocrevus Zunovo and Genentech Patient Foundation) and independent foundations (PAN Foundation, HealthWell Foundation, Good Days). Every program links directly to its official source or application page.
Last program check: .
Reviewed September 21, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost